IMCR Immunocore Holdings plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMCR

Price (delayed)

$60.23

Market cap

$3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.13

Enterprise value

$2.64B

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of ...

Highlights
The gross profit has increased by 43% year-on-year and by 7% since the previous quarter
The revenue is up by 43% year-on-year and by 6% since the previous quarter
IMCR's net income is up by 19% QoQ but it is down by 5% YoY
The debt has contracted by 4.5% from the previous quarter but it has grown by 3.2% YoY
Immunocore Holdings's quick ratio has decreased by 18% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://immunocore.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IMCR
Market
Shares outstanding
49.82M
Market cap
$3B
Enterprise value
$2.64B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.07
Price to sales (P/S)
11.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.59
Earnings
Revenue
$249.43M
EBIT
-$55.74M
EBITDA
-$50M
Free cash flow
-$2.49M
Per share
EPS
-$1.13
Free cash flow per share
-$0.05
Book value per share
$7.46
Revenue per share
$5.1
TBVPS
$12.21
Balance sheet
Total assets
$597M
Total liabilities
$228.16M
Debt
$84.03M
Equity
$368.84M
Working capital
$389.8M
Liquidity
Debt to equity
0.23
Current ratio
3.8
Quick ratio
3.56
Net debt/EBITDA
7.17
Margins
EBITDA margin
-20%
Gross margin
99.6%
Net margin
-22.2%
Operating margin
-23.9%
Efficiency
Return on assets
-9.8%
Return on equity
-15.5%
Return on invested capital
-59.5%
Return on capital employed
-12.2%
Return on sales
-22.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMCR stock price

How has the Immunocore Holdings stock price performed over time
Intraday
1.29%
1 week
3.03%
1 month
-5.52%
1 year
2.07%
YTD
-11.84%
QTD
-7.34%

Financial performance

How have Immunocore Holdings's revenue and profit performed over time
Revenue
$249.43M
Gross profit
$248.39M
Operating income
-$59.65M
Net income
-$55.29M
Gross margin
99.6%
Net margin
-22.2%
The gross profit has increased by 43% year-on-year and by 7% since the previous quarter
The revenue is up by 43% year-on-year and by 6% since the previous quarter
The net margin has grown by 26% YoY and by 24% from the previous quarter
The operating margin rose by 23% QoQ and by 20% YoY

Growth

What is Immunocore Holdings's growth rate over time

Valuation

What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
8.07
P/S
11.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.59
The EPS has grown by 22% since the previous quarter
The equity rose by 9% year-on-year
IMCR's price to book (P/B) is 2.2% more than its last 4 quarters average of 7.9
The revenue is up by 43% year-on-year and by 6% since the previous quarter
The stock's price to sales (P/S) is 4% less than its last 4 quarters average of 12.3

Efficiency

How efficient is Immunocore Holdings business performance
The ROIC has shrunk by 87% YoY and by 57% QoQ
The return on sales has declined by 46% since the previous quarter and by 10% year-on-year
The return on assets has increased by 22% since the previous quarter and by 16% year-on-year
The ROE is up by 21% since the previous quarter and by 18% year-on-year

Dividends

What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMCR.

Financial health

How did Immunocore Holdings financials performed over time
The total assets is 162% greater than the total liabilities
The total liabilities rose by 21% YoY and by 6% QoQ
The current ratio fell by 19% YoY and by 11% QoQ
The debt is 77% less than the equity
The equity rose by 9% year-on-year
The debt has contracted by 4.5% from the previous quarter but it has grown by 3.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.